Harnessing the potential of human lambda light chains in antibody discovery
Expanding antibody discovery potential with human lambda light chains
Despite the kappa/lambda ratio in human circulation being between 1.5 and 2, therapeutic antibodies remain heavily biased toward kappa light chain usage. Our white paper explores how Alloy’s ATX-GL platform transforms antibody discovery by unlocking the untapped potential of lambda light chains through:
- ATX-GL transgenic mouse models engineered specifically for lambda light chain antibody discovery
- Diverse lambda germline representation enabling broader epitope coverage
- Robust immune responses yielding a large pool of B cells producing diverse antibodies against desired target
- Complementary antibody discovery when paired with kappa light chain expressing
Complete this form to download the white paper
Overcome limitations in current antibody discovery
Lambda antibodies represent a significant opportunity for drug developers seeking novel binding properties and expanded therapeutic potential.
Discover how the ATX-GL platform enables:
- Access to novel epitopic diversity overlooked by conventional kappa-focused discovery
- Generation of lambda light chain antibodies with strong binding kinetics to target antigens
- Recovery of both lambda and kappa antibodies from a single immunization campaign
- Targeting of challenging antigens through unique physicochemical and structural properties of lambda light chains
